FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022121606> ?p ?o ?g. }

• W2022121606 endingPage "40" @default.
• W2022121606 startingPage "32" @default.
• W2022121606 abstract "The response of breast cancer patients to endocrine therapy is guided by the expression of two steroid hormone receptors (HR): estrogen receptor alpha (ERalpha) and/or progesterone receptors (PR). In most laboratories the expression of these predictive markers is studied by immunohistochemistry (IHC) in the breast cancer biopsy samples. Another molecular marker that is being increasingly examined in breast cancer is the oncoprotein Her-2/neu, whose expression/amplification predicts the response to anti-Her-2/neu immunotherapy. The co-expression of HR with that of Her-2/neu is infrequent (most reports agree on this), however, there are some conflicting reports about the clinical implications in term of response to endocrine therapy in the patients that co-express HR and Her-2/neu. We have examined these molecular markers for a number of years in our tumor bank, in this dissertation we will present the method and cut-off to study these markers, the correlations between their expression, and the follow-up of the patients that received tamoxifen-based endocrine therapy, alone or following chemotherapy. We confirmed that the co-expression of HR with Her-2/neu is infrequent, and that these patients presented both a shorter disease free survival and overall survival. Our results will be compared with others related recently published. For example, the aromatase inhibitor anastrozole appears to be an effective endocrine treatment in HR+ patients, irrespective of the Her-2/neu status. We will present data on the molecular mechanisms that could explain the relatively poor outcome of these patients. Heregulin has been found to be a potent inducer of heat shock factor 1 (HSF1) activity and of heat shock protein (Hsp) synthesis in breast cancer cells and HSF1 activation plays a role in the tumorigenic changes induced by heregulin, heregulin exerts its tumorigenic changes through the cell surface tyrosine kinase receptors c-erbB-3 and c-erbB-4 which are able to form dimers with the ligandless Her-2/neu. We found that HSF1 associates with metastasis associated protein 1 (MTA1) on the promoters of genes as well as other molecules involved in gene repression (HDAC1, HDAC2) in a manner that is enhanced by either heregulin exposure or heat shock. ERs, although promoting the growth of breast cancer cells are less associated with invasion/metastasis and ER-induced gene expression is involve in this effect. Heregulin can overcome the protective effects of ER and at least a component of this appears to be due to MTA1 repression of ERE dependent transcription, HSF1 and MTA1 cooperate in gene repression. The co-expression of HSF1 and MTA1 was confirmed by IHC in human breast cancer biopsy samples." @default.
• W2022121606 created "2016-06-24" @default.
• W2022121606 creator A5018799755 @default.
• W2022121606 creator A5032951976 @default.
• W2022121606 creator A5053278748 @default.
• W2022121606 creator A5081491953 @default.
• W2022121606 date "2006-12-01" @default.
• W2022121606 modified "2023-10-14" @default.
• W2022121606 title "Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications" @default.
• W2022121606 cites W1966623655 @default.
• W2022121606 cites W1975096943 @default.
• W2022121606 cites W1982388012 @default.
• W2022121606 cites W1983986715 @default.
• W2022121606 cites W1988561376 @default.
• W2022121606 cites W1989212867 @default.
• W2022121606 cites W1990582579 @default.
• W2022121606 cites W1991873634 @default.
• W2022121606 cites W2014031706 @default.
• W2022121606 cites W2021573784 @default.
• W2022121606 cites W2022742795 @default.
• W2022121606 cites W2023122724 @default.
• W2022121606 cites W2030888554 @default.
• W2022121606 cites W2033489089 @default.
• W2022121606 cites W2034943176 @default.
• W2022121606 cites W2035428017 @default.
• W2022121606 cites W2044342248 @default.
• W2022121606 cites W2049475256 @default.
• W2022121606 cites W2051622092 @default.
• W2022121606 cites W2053001792 @default.
• W2022121606 cites W2057733055 @default.
• W2022121606 cites W2058777032 @default.
• W2022121606 cites W2059345835 @default.
• W2022121606 cites W2062713892 @default.
• W2022121606 cites W2063874882 @default.
• W2022121606 cites W2063956958 @default.
• W2022121606 cites W2064347883 @default.
• W2022121606 cites W2066667289 @default.
• W2022121606 cites W2067199269 @default.
• W2022121606 cites W2081923162 @default.
• W2022121606 cites W2084653384 @default.
• W2022121606 cites W2098844349 @default.
• W2022121606 cites W2103012318 @default.
• W2022121606 cites W2104296738 @default.
• W2022121606 cites W2117666643 @default.
• W2022121606 cites W2125007784 @default.
• W2022121606 cites W2130074283 @default.
• W2022121606 cites W2133573009 @default.
• W2022121606 cites W2133886319 @default.
• W2022121606 cites W2135278339 @default.
• W2022121606 cites W2141232624 @default.
• W2022121606 cites W2143185770 @default.
• W2022121606 cites W2145257123 @default.
• W2022121606 cites W2148078311 @default.
• W2022121606 cites W2154142993 @default.
• W2022121606 cites W2156952931 @default.
• W2022121606 cites W2163250226 @default.
• W2022121606 cites W2165038925 @default.
• W2022121606 cites W2167129761 @default.
• W2022121606 cites W2170366015 @default.
• W2022121606 cites W2172175645 @default.
• W2022121606 cites W2175002425 @default.
• W2022121606 cites W2241097530 @default.
• W2022121606 cites W4255477022 @default.
• W2022121606 doi "https://doi.org/10.1016/j.jsbmb.2006.09.008" @default.
• W2022121606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17049840" @default.
• W2022121606 hasPublicationYear "2006" @default.
• W2022121606 type Work @default.
• W2022121606 sameAs 2022121606 @default.
• W2022121606 citedByCount "52" @default.
• W2022121606 countsByYear W20221216062012 @default.
• W2022121606 countsByYear W20221216062013 @default.
• W2022121606 countsByYear W20221216062014 @default.
• W2022121606 countsByYear W20221216062015 @default.
• W2022121606 countsByYear W20221216062016 @default.
• W2022121606 countsByYear W20221216062017 @default.
• W2022121606 countsByYear W20221216062018 @default.
• W2022121606 countsByYear W20221216062019 @default.
• W2022121606 countsByYear W20221216062021 @default.
• W2022121606 countsByYear W20221216062023 @default.
• W2022121606 crossrefType "journal-article" @default.
• W2022121606 hasAuthorship W2022121606A5018799755 @default.
• W2022121606 hasAuthorship W2022121606A5032951976 @default.
• W2022121606 hasAuthorship W2022121606A5053278748 @default.
• W2022121606 hasAuthorship W2022121606A5081491953 @default.
• W2022121606 hasConcept C121608353 @default.
• W2022121606 hasConcept C126322002 @default.
• W2022121606 hasConcept C134018914 @default.
• W2022121606 hasConcept C143998085 @default.
• W2022121606 hasConcept C170493617 @default.
• W2022121606 hasConcept C204232928 @default.
• W2022121606 hasConcept C2776166826 @default.
• W2022121606 hasConcept C2776215463 @default.
• W2022121606 hasConcept C2776888042 @default.
• W2022121606 hasConcept C2777164284 @default.
• W2022121606 hasConcept C2777176818 @default.
• W2022121606 hasConcept C2778504769 @default.
• W2022121606 hasConcept C46699223 @default.
• W2022121606 hasConcept C530470458 @default.

• next